ZLAB Expense Breakdown
Zai Lab Ltd (ZLAB). Quarter ended 2026-06-30 · each product line is listed as filed.
- 2026-06-30: Reportable $21.32M.
- 2025-06-30: Reportable $24.27M.
Expenses by product
General and Administrative Expense: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $21.32M |
| 2025-06-30 | $24.27M |
Research and development: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $61.77M |
| 2025-06-30 | $50.61M |
Research And Development Expense Clinical Programs: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $14.79M |
| 2025-06-30 | $16.97M |
Research And Development Expense Licensing Fees: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $15.00M |
| 2025-06-30 | $0.00 |
Research And Development Expense Personnel Compensation And Related Costs: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $22.71M |
| 2025-06-30 | $22.45M |
Research And Development Expense Pre Clinical Programs: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $19.61M |
| 2025-06-30 | $5.07M |
Research And Development Expense Unallocated Expense: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $27.36M |
| 2025-06-30 | $28.58M |
Selling And Marketing Expense: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $51.56M |
| 2025-06-30 | $46.76M |
Selling, General and Administrative Expense: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $72.87M |
| 2025-06-30 | $71.04M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |